Sponsors

Sponsorship packages for the 2026 conference are available:

Click here to see the 2026 options
Sponsors List
Compliance / Codex Publication List

Gold Sponsors 2026

Acuitas Therapeutics Inc., the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, is a Vancouver-based company collaborating with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines for a variety of diseases.

Acuitas’ clinically validated LNP technology has had a profound global impact — most notably enabling the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in more than 180 countries. Its technology also enables ONPATTRO® by Alnylam Pharmaceuticals, the first FDA-approved RNAi therapeutic for treating the rare and fatal disease transthyretin amyloidosis. More recently, Acuitas’ LNP technology has delivered other groundbreaking firsts: the first in-human proof of concept for genome base editing and the first personalized CRISPR therapy.

Today, Acuitas is advancing next-generation LNP to support a variety of therapeutic modalities. This includes targeted LNP for extrahepatic therapies such as in vivo CAR T-cells, gene editing therapies across multiple DNA editing technologies, epigenetic medicines to modulate gene expression without altering DNA, and multivalent vaccines for infectious diseases — such as malaria, HIV/AIDS, and tuberculosis — as well as oncology vaccines, including personalized cancer vaccines.

For more information, visit www.acuitastx.com.

Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, mRNA, proteins, and other key components for the development of vaccines, gene and cell therapies, immunotherapies and other treatments. As a part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. To learn more about how Aldevron is advancing biological science, visit www.aldevron.com/about-us.

FUJIFILM Corporation offers cutting-edge mRNA/LNP services. There is a variety of proprietary ionizable lipids available, like ones for vaccine use already in Phase 3, ones for i.v. with more expression in the liver and lower liver enzyme elevation in NHP, ones for liver de-targeting, and ex-vivo LNPs for KO/KI.
CDMO services from laboratory to commercial use are also available with high-quality and dedicated customer support.

Genevant Sciences is a leading nucleic acid delivery solutions company with best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology. Our selective collaboration business model enables us to partner with innovative payload companies in the gene editing, and RNA editing, therapeutic and vaccine spaces to bring emerging technologies into and through the clinic.

Our leadership position, built over more than two decades focused on nucleic acid development and delivery, is reflected in the first approved RNA-LNP product (Onpattro® marketed by Alnylam), the COVID-19 vaccine Spikevax® (marketed by Moderna), and the industry’s most robust and expansive LNP patent portfolio. We have generated a comprehensive data package in our current research focus centered around expanding the therapeutic reach of LNPs to T cells, hematopoietic stem cells (HSC) and other traditionally hard to reach tissues/cell types.

We look forward to partnering with biopharma companies to bring innovative therapies to the patient.

Millipore Sigma is the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany. We provide solutions to help you overcome your lipid manufacturing and LNP formulation challenges. Our CDMO capabilities include the development and manufacturing of custom and off-the-shelf lipids, lipid nanoparticle (LNP) formulation and manufacturing and Fill and Finish. Discover how our capabilities, technical expertise and regulatory know-how can help you deliver and scale up your lipid-based therapeutics, accelerate time to market and mitigate risks.

www.SigmaAldrich.com/MilliporeCTDMOServices

Moderna is one of the leaders in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made with the goal of transforming how we treat and prevent disease for everyone. For more than a decade we have been pioneering the potential of mRNA to develop therapeutics and vaccines for infectious diseases, immuno-oncology, and rare diseases.

Polymun Scientific GmbH

is a private Austrian company, located in Klosterneuburg, offering contract development and manufacturing of biopharmaceuticals as well as development and production of LNP and liposomal formulations. Its patented liposome/LNP technology allows efficient manufacturing of constantly high quality in small and large scale. Over the last 15 years, Polymun has guided LNP and liposomal formulations into clinical trials, amongst them DNA and different kinds of RNA formulations. A prominent example is Polymun’s contribution to the BioNTech/Pfizer Covid-19 vaccine. Here the team at Polymun Scientific has significantly contributed to the 1st successful mRNA vaccine Comirnaty by optimizing and up-scaling the LNP process as well as by supporting clinical and early market supply.

Polymun is an FDA- and EMA-inspected manufacturer conducting several own R&D projects. For more information, please visit www.polymun.com

From vaccines and immunotherapies to protein replacement and cell reprogramming, interest in mRNA manufacturing has surged. Decades before the pandemic, Roche CustomBiotech has supplied nucleotides and enzymes for mRNA production. We work with many pioneering mRNA companies to develop and manufacture needed raw material solutions. In collaboration with therapeutic manufacturers, our portfolio has evolved to meet the changing needs of the mRNA field. Always abreast with market developments, Roche CustomBiotech enables a new generation of mRNA therapeutics. Our guiding tenet is to minimize variation of products built on our raw materials by ensuring best quality, high performance within narrow tolerances, and reliable delivery.
Remaining at the front of this fast-paced therapeutic space hinges not only on ideas and implementation, but also on speed and quality. Your expertise is coming up with the idea and the implementation; as a long-standing global supplier, Roche CustomBiotech’s expertise in raw materials can help you accelerate development and ensure high quality mRNA. We help you strengthen your supply chain, ease transfers to manufacturing, secure continuous production, and create consistently high-quality products.
Raw materials for mRNA therapeutics and vaccines

Vazyme (688105.SH) is a global biotech supplier dedicated to advancing life science through innovative enzyme technology. To meet the varying needs of our customers and partners, we have developed over 1,000 types of genetically engineered recombinant enzymes, over 3,000 types of high-performance materials, and nearly 3,000 end products. By upholding rigorous quality standards and producing all molecular materials in-house, we guarantee a consistent and dependable supply to our global customers. 

Silver Sponsors 2026

ARCALIS is a CDMO specializing in messenger RNA (mRNA) medicines and vaccines.

The company was established as a joint venture between Axcelead, Inc., Japan’s first drug discovery platform company, and Arcturus Therapeutics, a US-based clinical-stage mRNA therapeutics company.

In July 2023, ARCALIS launched a GMP-compliant mRNA drug substance manufacturing facility in Japan, further strengthening its integrated development and manufacturing capabilities.

In 2024, the company achieved a major milestone with the world’s first commercial production of a self-amplifying mRNA vaccine against COVID-19.

mRNA technology is driving innovation beyond infectious diseases, with expanding applications in rare diseases, oncology, regenerative medicine, and genome-editing therapies.

Leveraging deep expertise in mRNA development and manufacturing, ARCALIS supports clients from early-stage research through to commercial production, ensuring a reliable supply of high-quality mRNA.

In addition, ARCALIS provides:

  • High-throughput, small-scale, multi-product services optimized for target selection and LNP (lipid nanoparticle) screening
  • Flexible engagement options, including standalone consultation for fill-finish operations at our DP (drug product) facility
    Our website TOP PAGE｜ARCALIS, Inc.

Eclipsebio is a private biotechnology company headquartered in San Diego that combines AI-powered sequence design, rapid prototyping, and sequencing-based analytics to support RNA drug development. With extensive experience supporting early-stage basic research through preclinical therapeutic development, Eclipsebio provides unparalleled support for obtaining deep insights into RNA and therapeutic biology. The company offers its solutions as end-to-end partnerships for biopharma and project-based services for academics. For more information about Eclipsebio, visit www.eclipsebio.com.

Since 1998, Hongene Biotech has been a trusted name in nucleic acid manufacturing. Backed by nearly 30 years of RNA-focused expertise, we partner with biotech and pharma innovators to accelerate development with precision and purpose. Our vertically-integrated model — spanning raw materials to advanced CDMO services — reduces handoffs, shortens timelines and lowers risk across the value chain.

Lonza is the world’s leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry. Working across five continents, Lonza’s global team of approximately 20,000 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. This enables customers to bring life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing.

Primrose Bio develops and commercializes manufacturing technologies that close gaps in biologics, mRNA and vaccine production. Primrose’s major offerings include Pfenex Expression Technology®: a proprietary microbial production system used in six approved products with up to 20x higher yields and a strong record across diverse protein modalities; Prima RNApols®: improved enzymes for mRNA manufacturing; and PeliCRM197®: a commercially validated CRM197 carrier protein used for conjugate vaccines.  Several of the world’s leading pharmaceutical companies use Primrose’s technologies in marketed products, including Merck, Jazz Pharmaceuticals, Alvogen, and Serum Institute of India. For more information, please visit: visit: www.primrosebio.com.

Sartorius is a leading global partner of the biopharmaceutical industry dedicated to enabling cell and gene therapy developers to manufacture and commercialize their advanced therapy medicinal products (ATMPs). Over the last decade the company has expanded its legacy portfolio of single-use bioprocessing solutions through the acquisition of complementary advanced therapy consumables, services, and technologies—from plasmid engineering and manufacturing to cell culture media, reagents and monolithic chromatography. Sartorius’ advanced therapy solutions are designed to overcome current ATMP production challenges by enhancing productivity, improving process economics, and supporting safe and regulatory compliant manufacturing. Sartorius products are currently used in approved cell and gene therapies and actively support clinical pipelines worldwide. The company’s continued investment in innovative solutions demonstrates their commitment to advancing the field and making access to these life-saving treatments a reality.  

TriLink BioTechnologies, part of Maravai LifeSciences, is a best-in-class contract development and manufacturing organization (CDMO) for the synthesis of nucleic acids, NTPs and mRNA capping analogs. TriLink has scale-up expertise and unique mRNA, oligonucleotide & plasmid production capabilities for companies focused on therapeutic, vaccine, diagnostic and biopharmaceutical breakthroughs. Biopharma companies turn to TriLink as a critical supplier of modified nucleic acids and as a CDMO partner to help them move from early research into clinical trials.

Wacker Biotech is the global biologics expert CDMO partner for advanced nucleic acid-based therapeutics. We offer a fully integrated nucleic acid manufacturing platform to enable seamless production of plasmid DNA (pDNA), IVT of RNA, lipid nanoparticle (LNP) formulation, and protein conjugation for targeted LNPs. Via our proprietary PLASMITEC® platform, we also produce high-quality plasmids (up to 98% supercoiled) for DNA vaccines and viral vector gene and cell therapies.

Offering expert guidance and scientific problem-solving throughout the development lifecycle, we flexibly serve diverse customer needs ranging from R&D quality and scale to High Quality to GMP manufacturing for clinical and commercial supply. Our sites in Germany, the Netherlands and USA include a state-of-the-art RNA competence center in Halle, Germany and a pDNA center of excellence in San Diego, California, USA. Complementing these sites is a dedicated R&D center in Munich, Germany with scientific experts leading groundbreaking nucleic acid research, technology innovations, and collaborations.

Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20th century’s leading biochemistry advances. We have 30+ years of experience developing biologics to advance human and animal health. For more information, visit: www.wacker.com/biologics

Bronze Sponsors 2026

4basebio is a GMP-certified manufacturer of synthetic DNA, advancing next-generation cell and gene therapies and vaccines with fast, flexible, and high-purity synthetic nucleic acid solutions.

We design, manufacture, and supply application-specific synthetic DNA and mRNA. Our novel enzymatic DNA synthesis platform offers unique customization potential, rapid turnaround times, and enhanced safety compared to traditional plasmid DNA.

Our clinically validated opDNA® construct is optimized for mRNA production, eliminating the need for enzymatic linearization and enabling dose reductions, increased purity, and greater consistency.

To learn more, visit https://www.4basebio.com/.

Anemocyte is an italian Biotech Manufacturing Organization with a strong focus on the research, development, manufacturing and analyical services and products to address needs in the field of mRNA and pDNA.

Anemocyte could significantly support your programs offering a range of services and products that includes:

– AMCAP™ (mRNA Synthesis): Our high-yield 5′ CAP-1 “one-pot” process. Designed for less complexity and higher integrity. anemocyte.com/amcap/

– pDNA and mRNA Development & Manufacturing Platforms: Scaling your innovation from lab to commercial, leveraging more than 25 years of GMP experience. anemocyte.com

– AMCLARITY (Visual Inspection Defect Kits): Advanced automated quality control solutions for uncompromising consistency. anemocyte.com/amclarity/

For a quick preview of our ecosystem, you can also visit: shop.anemocyte.com | AMCAP™

Biomay is an FDA approved CDMO for cGMP manufacturing of mRNA (including LNP formulation), plasmid DNA (circular or linear) and recombinant proteins (e.g. Cas9). Our end-to-end service portfolio ranges from cell line development to aseptic filling. In addition, Biomay distributes GMP-conform catalog products off-the shelf, like starting plasmids for AAV / LV, or recombinant Cas9 as nuclease or mRNA

Founded in the mid-1970s as a collective of scientists committed to developing innovative products for the life sciences industry, New England Biolabs is proud to be a world leader in the discovery and production of enzymes for molecular biology applications.

The mission of CELLSCRIPT™ is to provide high quality products and technologies for making and using RNA for translation in cells for clinical research and therapeutics.

CELLSCRIPT™, based in Madison, WI, is an innovative company dedicated to developing user-friendly, cutting-edge enzyme solutions for mRNA research. CELLSCRIPT™ has consistently delivered reliable, high-quality reagents and RNA kits trusted by scientists in academic, governmental, biotech, and pharmaceutical organizations. As the RNA field continues to grow and evolve, we remain dedicated to introducing new products that meet the needs of scientists worldwide. CELLSCRIPT™ provides a broad range of products for mRNA synthesis from in vitro transcription to quality control assays. Current products include kits for in vitro transcription, RNA 5’-end capping using either capping enzymes or a cap analog, and RNA 3’-end polyadenylation, as well as all-in-one kits for making capped, poly(A)-tailed mRNA for translation in cells. Additional offerings include a novel kit for the removal of dsRNA from RNA preps and assays to easily analyze the quality of final mRNA products. CELLSCRIPT also offers research grade and cGMP custom CDMO mRNA services to support customers from early discovery to clinical trials and beyond.

Evonik Health Care is a business line of Evonik Corporation, one of the world’s leading specialty chemicals companies. The Health Care business serves as a global innovation partner to pharmaceutical, biotechnology, medical device, and nutraceutical companies, helping develop and manufacture advanced therapies that improve patient outcomes.

Here’s the deal. We’re all about helping biologics and gene therapy researchers break free from tools that just don’t cut it. Unleashing problem-tackling solutions and AI-driven automation that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it.

RIBOPRO offers a range of services and technologies that enable mRNA therapy pioneers to develop the medicines of the future. We invest heavily in R&D, knowledge and product quality, to deliver you the best.

From mRNA design, development of targeted LNP formulations, Research- and GMP-grade manufacturing of (LNP-formulated) mRNA, and contract research services; our integrated offering has got you covered during all of your project development phases.

Even better, our licensable technologies on mRNA design, manufacturing processes and LNP formulations provide a head start in the competitive marketplace.

leon-nanodrugs GmbH specializes in the development of equipment for the encapsulation of genetic material and other pharmaceutical active substances into nanocarriers, such as lipid nanoparticles (LNPs). The company leverages its proprietary FR-JET® technology to build innovative solutions. Its equipment portfolio includes NANOscreen® for formulation screening, NANOlab® for process development, as well as NANOme® and NANOus® for GMP manufacture. These systems are suitable for both individualized scales and large-scale commercial production. LEON’s platform solves scale-up unpredictability: consistent mixing from lab to GMP scale cuts re-optimization and CMC disruption risk – the real cost isn’t lost materials, it’s lost time to process lock, clinical milestones, and ultimately product NPV.

Marama Labs develops spectroscopy technology for characterising lipid nanoparticles and other turbid biological samples. Its flagship instrument, CloudSpec, uses patented Scatter-Free Absorbance technology to directly measure RNA payload, encapsulation efficiency and ligands in intact lipid nanoparticles. Measurements that once required complex assays and hours of preparation can now be completed in seconds.

Wacker Biotech is the global biologics expert CDMO partner for advanced nucleic acid-based therapeutics. We offer a fully integrated nucleic acid manufacturing platform to enable seamless production of plasmid DNA (pDNA), IVT of RNA, lipid nanoparticle (LNP) formulation, and protein conjugation for targeted LNPs. Via our proprietary PLASMITEC® platform, we also produce high-quality plasmids (up to 98% supercoiled) for DNA vaccines and viral vector gene and cell therapies.

Offering expert guidance and scientific problem-solving throughout the development lifecycle, we flexibly serve diverse customer needs ranging from R&D quality and scale to High Quality to GMP manufacturing for clinical and commercial supply. Our sites in Germany, the Netherlands and USA include a state-of-the-art RNA competence center in Halle, Germany and a pDNA center of excellence in San Diego, California, USA. Complementing these sites is a dedicated R&D center in Munich, Germany with scientific experts leading groundbreaking nucleic acid research, technology innovations, and collaborations.

Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20th century’s leading biochemistry advances. We have 30+ years of experience developing biologics to advance human and animal health. For more information, visit: www.wacker.com/biologics

Wacker Biotech is the global biologics expert CDMO partner for advanced nucleic acid-based therapeutics. We offer a fully integrated nucleic acid manufacturing platform to enable seamless production of plasmid DNA (pDNA), IVT of RNA, lipid nanoparticle (LNP) formulation, and protein conjugation for targeted LNPs. Via our proprietary PLASMITEC® platform, we also produce high-quality plasmids (up to 98% supercoiled) for DNA vaccines and viral vector gene and cell therapies.

Offering expert guidance and scientific problem-solving throughout the development lifecycle, we flexibly serve diverse customer needs ranging from R&D quality and scale to High Quality to GMP manufacturing for clinical and commercial supply. Our sites in Germany, the Netherlands and USA include a state-of-the-art RNA competence center in Halle, Germany and a pDNA center of excellence in San Diego, California, USA. Complementing these sites is a dedicated R&D center in Munich, Germany with scientific experts leading groundbreaking nucleic acid research, technology innovations, and collaborations.

Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20th century’s leading biochemistry advances. We have 30+ years of experience developing biologics to advance human and animal health. For more information, visit: www.wacker.com/biologics

Basic Sponsors 2026

As one of the largest independent contract laboratories in Europe, Labor LS provides analytical services to more than 1,000 clients according to cGMP standards in the fields of microbiology, biochemistry, molecular biology, and chemical-physical analysis. 
With the goal of offering comprehensive, one-stop services to support the development and release of the most advanced pharmaceutical products, Labor LS carries out method validations, verifications, and routine testing with over 600 experts and approximately 7,000 m² of laboratory space, working in close cooperation with its customers.

Immagina Bio advances RNA and ribosome biology by enabling scientists to study translation in action. Our integrated suite of technologies—including high-throughput ribosome profiling, ribosome isolation, native-tRNA sequencing, cell-free RNA fragmentomics, and RNA modification detection—delivers unprecedented insights into protein synthesis. We empower academic researchers and pharmaceutical companies to develop more efficient, effective, and safer therapeutics, along with more informative biomarkers

preclinics GmbH is a Potsdam (GER) -based leading Contract Research Organization (CRO). We are specialized in the early preclinical development of biologics, vaccines, and therapeutic candidates. Our integrated preclinical services accelerate the translation of mRNA-based therapies and vaccines from bench to clinic. 

With more than 15 years of scientific excellence, preclinics combines cutting-edge technologies, comprehensive in vitro and in vivo models, and a collaborative mindset to deliver high-quality, reliable data for decision-making in drug development. 

Our preclinical portfolio covers: 

  • Translational in vivo PK/PD models for mRNA delivery systems 
  • Reporter gene analysis via in vivo imaging, ddPCR and protein quantification 
  • Biomarker-driven efficacy studies. 
  • Immunogenicity and antibody response profiling for mRNA candidates. 
  • Formulation testing and comparative studies for LNP and non-LNP technologies.

     

We invite you to visit our representative to discuss how preclinics can advance your mRNA program — from concept to preclinical validation. 

Driven by innovation and a strong commitment to scientific integrity, animal welfare, and the 3R principles, and as a signatory of the Marseille Declaration, preclinics is your trusted partner for translational preclinical solutions that move ideas efficiently and responsibly toward clinical success. 

In collaboration with Taconic Biosciences, preclinics provides access to 4.600 transgene models and custom GEM services, empowering our partners to explore disease mechanisms and validate therapeutic targets with exceptional translational relevance. 

For more information please visit www.preclinics.com